Document is current

Article History

Received: 9 July 2024

Revised: 18 August 2024

Accepted: 23 August 2024

First Online: 30 August 2024

Declarations

:

: Prof Rui Araújo received speaking fees from Bial. Prof Noyce reports grants from Parkinson's UK, Barts Charity, Cure Parkinson’s, National Institute for Health and Care Research, Innovate UK, Virginia Keiley benefaction, Solvemed, the Medical College of Saint Bartholomew’s Hospital Trust, Alchemab, Aligning Science Across Parkinson’s Global Parkinson’s Genetics Program (ASAP-GP2), and the Michael J Fox Foundation. Prof Noyce reports consultancy and personal fees from AstraZeneca, AbbVie, Profile, Bial, Charco Neurotech, Alchemab, Sosei Heptares, Umedeor, and Britannia. Prof Noyce has share options in Umedeor. Prof Noyce is an Associate Editor for the Journal of Parkinson’s Disease. Outside the present work, Prof Bloem has the following to report. He is co-Editor-in-Chief for the Journal of Parkinson’s disease. He is on the editorial board of Practical Neurology and Digital Biomarkers, has received honoraria from being on the scientific advisory board for Abbvie, Biogen, and UCB, has received fees for speaking at conferences from AbbVie, Zambon, Roche, GE Healthcare, and Bial, and has received research support from the Netherlands Organization for Scientific Research, the Michael J Fox Foundation, UCB, Not Impossible, the Hersenstichting Nederland, the Parkinson’s Foundation, Verily Life Sciences, Horizon 2020, and the Parkinson Vereniging (all paid to the institute).

: The authors confirm that the approval of an institutional review board was not required for this work. Also, patient consent was not required. We confirm that we have read the Journal’s position on issues involved in ethical publication and affirm that this work is consistent with those guidelines.